Lentiviral Vector Preparation for Efficient Gene and MicroRNA Modulation of Peritoneal Cavity Tissue-Resident Macrophages In Vivo in Mice
Summary
We demonstrate a step-by-step protocol for the investigation of gene function in peritoneal tissue-resident macrophages in vivo, using lentiviral vectors.
Abstract
Peritoneal tissue-resident macrophages have broad functions in the maintenance of homeostasis and are involved in pathologies within local and neighboring tissues. Their functions are dictated by microenvironmental cues; thus, it is essential to investigate their behavior in an in vivo physiological niche. Currently, specific peritoneal macrophage-targeting methodologies employ whole-mouse transgenic models. Here, a protocol for effective in vivo modulation of mRNA and small RNA species (e.g., microRNA) expression in peritoneal macrophages using lentivirus particles is described. Lentivirus preparations were made in HEK293T cells and purified on a single sucrose layer. In vivo validation of lentivirus effectivity following intraperitoneal injection revealed predominant infection of macrophages restricted to local tissue. Targeting of peritoneal macrophages was successful during homeostasis and thioglycolate-induced peritonitis. The limitations of the protocol, including low-level inflammation induced by intraperitoneal delivery of lentivirus and time restrictions for potential experiments, are discussed. Overall, this study presents a quick and accessible protocol for the rapid assessment of gene function in peritoneal macrophages in vivo.
Introduction
Tissue-resident macrophages (Mφ) are a heterogeneous population of phagocytic immune cells that sense and respond to invading pathogens1,2. In addition, they play an essential role in tissue development, remodeling, and maintaining homeostasis1,3. Many tissue Mφ derive from yolk sac progenitors during embryogenesis and persist in the tissue throughout the life4,5. The phenotype and functions of these cells are dictated by collaborative and hierarchical interactions of specific transcription factors and the local microenvironment6,7,8,9. A growing understanding of this dependency increases the need for effective in vivo methods for gene manipulation of Mφ within their physiologically relevant niche.
Lentiviral vectors are a frequently employed tool for the manipulation of nucleic acids in specific cell populations in vivo10,11,12, particularly due to their ability to infect both dividing and non-dividing cells and to stably integrate into host genome13,14. Over the last two decades, lentivirus delivery technology has been optimized, and alternative envelopes and synthetic promoters have been investigated to increase lineage-specific targeting8,15. Owing to its broad cell tropism, vesicular stomatitis virus envelop glycoprotein (VSV-G)16,17 has become the "gold-standard" envelope used in lentivirus technology.
In this protocol18, VSV-G pseudotyped lentiviral particles are employed to demonstrate targeted and effective delivery of short hairpin RNA (shRNA) and microRNA (miR) to mouse peritoneal Mφ (pMφ) in vivo, at steady state19. Transgene expression was driven by the spleen focus forming virus (SFFV) promoter. Productive infection of cells was defined by expression of lentivirus-derived enhanced green fluorescent protein (GFP). Utilization of this approach allowed easy readout for in vivo lentivirus experiments to define the optimal dose and the experimental timeframe. Finally, in vivo lentiviral challenge of mice during thioglycolate-induced inflammation revealed the natural propensity for selective pMφ infection.
Protocol
Representative Results
Discussion
Tissue-resident macrophages perform a range of homeostatic and inflammatory tissue-specific functions1,2 dictated by their physiological environment6,7,8,9. In this protocol, an effective method18 for manipulation of peritoneal resident macrophages in vivo using lentivirus particles was introduced to inv…
Declarações
The authors have nothing to disclose.
Acknowledgements
This research was funded, in whole or in part, by the Wellcome Trust Investigator Award [107964/Z/15/Z]. P.R.T is also supported by the UK Dementia Research Institute. M.A.C is supported by the Biotechnology and Biological Sciences Research Council Discovery Fellowship (BB/T009543/1). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. L.C.D is a lecturer at Swansea University and an honorary research fellow at Cardiff University. This work is supported by work carried out by Ipseiz et al. 202018.
Materials
| 0.05% Trypsin-EDTA (1x) (Trypsin 500 mg/L or 0.02 mM) | Thermo Fisher Scientific | 25300054 | |
| 0.22 μm sterile millex GP filter | Merck | SLGS033SS | |
| 0.45 μm sterile millex GP filter | Merck | SLHP033RS | |
| 0.5 mL U-100 insulin syringe with needle, 0.33 mm x 12.7 mm (29 G) | BD | 324892 | |
| 1 Litre Sharps Container | N/A | N/A | |
| 2.4G2 antibody (TruStain FcX anti-mouse CD16/32) | Biolegend | 101320 | |
| 40 μm strainer | Thermo Fisher Scientific | 22363547 | |
| AimV medium (research grade), AlbuMax Supplement | Thermo Fisher Scientific | 31035025 | |
| Blocking buffer | prepared in house | ||
| Brewer thioglycolate medium | Sigma-Aldrich | B2551 | 4% stock solution prepared in water, autoclaved and kept frozen. |
| CD11b | Biolegend | 101222 | Refer to Table 1 for the dilution and concentration |
| CD11b | BD | 550993 | Refer to Table 1 for the dilution and concentration |
| CD11c | Biolegend | 117317 | Refer to Table 1 for the dilution and concentration |
| CD11c | Biolegend | 117333 | Refer to Table 1 for the dilution and concentration |
| CD19 | BD | 560375 | Refer to Table 1 for the dilution and concentration |
| CD19 | Biolegend | 152410 | Refer to Table 1 for the dilution and concentration |
| CD226 | Biolegend | 128808 | Refer to Table 1 for the dilution and concentration |
| CD3e | BD | 560527 | Refer to Table 1 for the dilution and concentration |
| CD3e | Biolegend | 152313 | Refer to Table 1 for the dilution and concentration |
| CD4 | Biolegend | 100412 | Refer to Table 1 for the dilution and concentration |
| CD73 | eBioscience | 16-0731-82 | Refer to Table 1 for the dilution and concentration |
| CD8a | eBioscience | 48-0081-82 | Refer to Table 1 for the dilution and concentration |
| Cell culture flask (T175 fask, 175 cm2, 550 mL) | Greiner Bio One | 658175 | |
| Centrifuge tubes, conical bottom tubes 25 mm x 89 mm | Beckman Coulter | 358126 | |
| Centrifuges | Beckman Coulter | Ultracentrifuge and TC centrifuge | |
| Collagenase type IV | Sigma-Aldrich | C5138 | |
| Conical centrifuge tubes (15 mL and 50 mL) | Greiner Bio One | 11512303 & 11849650 | |
| Cryotubes | Greiner Bio One | 123277 | or cryotubes |
| DMEM medium (1x) + 4.5g/L D-glucose, 400 µM L-glutamine | Thermo Fisher Scientific | 41965-062 | |
| Dnase I | Sigma-Aldrich | 11284932001 | |
| Effectene transfection reagent | Qiagen | 301425 | |
| F4/80 | Biolegend | 123123 | Refer to Table 1 for the dilution and concentration |
| F4/80 | Biolegend | 123133 | Refer to Table 1 for the dilution and concentration |
| F4/80 | Biolegend | 123147 | Refer to Table 1 for the dilution and concentration |
| FceR1 | eBioscience | 48-5898-80 | Refer to Table 1 for the dilution and concentration |
| Fetal calf serum (FCS) | Thermo Fisher Scientific | 10270-106 | heat inactivated for 30 min at 56 °C and sterile filtered through 0.22 μm filter |
| Flow cytometer | Thermo Fisher Scientific | Attune NxT | |
| Flow cytometry (FACS) buffer | prepared in house | ||
| Fluorescent tissue culture microscope | Thermo Fisher Scientific | EVOS FL | |
| Forceps | N/A | N/A | User preference |
| Hank's balanced salt solution (HBSS) | Gibco, Life Technologies | 14175-053 | |
| HEK293T cell line | grown for at least a week prior transfection. Mycoplasma free | ||
| HIV-1 Core antigen | Beckman Coulter | 6604667 | |
| Hyaluronidase | Sigma-Aldrich | H3506 | |
| Hydrex surgical scrub, chlorhexiding gluconate 4% w/v skin cleanser | Ecolab | 3037170 | |
| I-A/I-E | Biolegend | 107625 | Refer to Table 1 for the dilution and concentration |
| ICAM1 | Becton Dickinson | 554970 | Refer to Table 1 for the dilution and concentration |
| Jurkat T cell line | grown for at least a week prior use. Mycoplasma free | ||
| LIVE/DEAD fixable near-IR dead cell stain kit | Thermo Fisher Scientific | L34975 | |
| Ly6G | Biolegend | 127615 | Refer to Table 1 for the dilution and concentration |
| Mice | here used C57BL/6 females, aged 8-12 weeks (Charles Rivers), unless specified differently | ||
| Microcapillary pipettes (volume range 0.5-1,000 μL) | Fisher Scientific & Starlab | 11963466 & 11943466 & 11973466 & S1111-3700 | |
| NK1.1 | Biolegend | 108724 | Refer to Table 1 for the dilution and concentration |
| Paraformaldehyde | Sigma-Aldrich | P6148-500G | prepared to 2% w/v in PBS |
| pCMV-ΔR8.91 packaging plasmid | Zuffrey, R., et al. 1997 | encodes Gag-Pol HIV protein driven by cytomegalovirus promoter. Ampicilin resistance. | |
| Penicillin/Streptomycin (100x, 10,000 U/mL) | Thermo Fisher Scientific | 15140122 | |
| Petri dish | Greiner Bio One | 664160 | |
| pHR'SIN-cPPT-SEW plasmid | Rosas, M. et al. 2014 | modified for shRNA and miR expression studies. Encodes EGFP marker downstream SFFV promoter and upstream of the Woodchuck hepatitiv virus enhancer. Ampicilin resistance. | |
| pMD2.G plasmid | Naldini, L. et al. 1996 | encodes vesicular stomatis virus g-glycoprotein (VSV-G) envelope. Ampicilin resistance. | |
| Rat IgG1, κ isotype control | Becton Dickinson | 550617 | Refer to Table 1 for the dilution and concentration |
| Rat serum | Sigma-Aldrich | R9759-10ML | |
| Red blood ACK lysis buffer | prepared in house | ||
| RPMI 1640 medium (1x) + 400 uM L-glutamine | Thermo Fisher Scientific | 21875-091 | |
| Saponin | Sigma-Aldrich | S4521 | |
| SiglecF | BD | 562681 | Refer to Table 1 for the dilution and concentration |
| Sodium hypochlorite Tablets (bleach, 2,000 ppm) | Guest Medical | H8818 | |
| Sterile 24-well cell culture plate | Greiner Bio One | 662160 | |
| Sterile Dulbecco's PBS (DPBS) (1x) Mg++ and Ca2+ – free | Thermo Fisher Scientific | 14190144 | |
| Sterile EDTA | Thermo Fisher Scientific | 15575020 | |
| Sterile VWR disposable transfer pipets (23.0 mL, 30 cm) | VWR | 612-4515 | |
| Sucrose | Thermo Fisher Scientific | 15503022 | |
| surgical scissors | N/A | N/A | User preference |
| Syringes (50 mL and 1 0mL) | Fisher Scientific | 10084450 & 768160 | |
| Tim4 | Biolegend | 130007 | Refer to Table 1 for the dilution and concentration |
| U-bottom 96-well cell culture plate | Greiner Bio One | 650180 |
Referências
- Wynn, T. A., Chawla, A., Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature. 496 (7446), 445-455 (2013).
- Jantsch, J., Binger, K. J., Muller, D. N., Titze, J. Macrophages in homeostatic immune function. Front Physiol. 5, 146 (2014).
- Wynn, T. A., Vannella, K. M. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 44 (3), 450-462 (2016).
- Ginhoux, F., Guilliams, M. Tissue-resident macrophage ontogeny and homeostasis. Immunity. 44 (3), 439-449 (2016).
- Epelman, S., Lavine, K. J., Randolph, G. J. Origin and functions of tissue macrophages. Immunity. 41 (1), 21-35 (2014).
- Amit, I., Winter, D. R., Jung, S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat Immunol. 17 (1), 18-25 (2016).
- Gosselin, D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 159 (6), 1327-1340 (2014).
- Lavin, Y., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 159 (6), 1312-1326 (2014).
- Davies, L. C., et al. Peritoneal tissue-resident macrophages are metabolically poised to engage microbes using tissue-niche fuels. Nat Commun. 8 (1), 2047 (2017).
- Shi, J., Hua, L., Harmer, D., Li, P., Ren, G. Cre driver mice targeting macrophages. Methods Mol Biol. 1784, 263-275 (2018).
- Wang, X., et al. Recent advances in lentiviral vectors for gene therapy. Sci China Life Sci. 64 (11), 1842-1857 (2021).
- Kosaka, Y., et al. Lentivirus-based gene delivery in mouse embryonic stem cells. Artif Organs. 28 (3), 271-277 (2004).
- Naldini, L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272 (5259), 263-267 (1996).
- Yamashita, M., Emerman, M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol. 78 (11), 5670-5678 (2004).
- Wilson, A. A., et al. Lentiviral delivery of RNAi for in vivo lineage-specific modulation of gene expression in mouse lung macrophages. Mol Ther. 21 (4), 825-833 (2013).
- Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 90 (17), 8033-8037 (1993).
- Finkelshtein, D., Werman, A., Novick, D., Barak, S., Rubinstein, M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A. 110 (18), 7306-7311 (2013).
- Ipseiz, N., et al. Effective in vivo gene modification in mouse tissue-resident peritoneal macrophages by intraperitoneal delivery of lentiviral vectors. Mol Ther Methods Clin Dev. 16, 21-31 (2020).
- Rosas, M., et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science. 344 (6184), 645-648 (2014).
- . Available from: https://www.mybeckman.uk/resources/technologies/centrifugation/principles/rotor-balancing (2023)
- JoVE Science Education Database. Lab Animal Research. Rodent Handling and Restraint Techniques. , (2023).
- Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 15 (9), 871-875 (1997).
- Nasri, M., Karimi, A., Allahbakhshian Farsani, M. Production, purification and titration of a lentivirus-based vector for gene delivery purposes. Cytotechnology. 66 (6), 1031-1038 (2014).
- al Yacoub, N., Romanowska, M., Haritonova, N., Foerster, J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med. 9 (7), 579-584 (2007).
- Malim, M. H., Bieniasz, P. D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med. 2 (5), a006940 (2012).
- Sonza, S., et al. Susceptibility of human monocytes to HIV type 1 infection in vitro is not dependent on their level of CD4 expression. AIDS Res Hum Retroviruses. 11 (7), 769-776 (1995).
- Kingston, R. E., Chen, C. A., Rose, J. K. Calcium phosphate transfection. Curr Protoc Mol Biol. Chapter 9, Unit 9.1 (2003).
- Brown, L. Y., Dong, W., Kantor, B. An Improved protocol for the production of lentiviral vectors. STAR Protoc. 1 (3), 100152 (2020).
- Moce-Llivina, L., Jofre, J., Muniesa, M. Comparison of polyvinylidene fluoride and polyether sulfone membranes in filtering viral suspensions. J Virol Methods. 109 (1), 99-101 (2003).
- Jiang, W., et al. An optimized method for high-titer lentivirus preparations without ultracentrifugation. Sci Rep. 5, 13875 (2015).
- Czubala, M. A., et al. TGFbeta induces a SAMHD1-independent post-entry restriction to HIV-1 infection of human epithelial langerhans cells. J Invest Dermatol. 136 (10), 1981-1989 (2016).
- Bouabe, H., Okkenhaug, K. Gene targeting in mice: a review. Methods Mol Biol. 1064, 315-336 (2013).
- Kim, J. M., Rasmussen, J. P., Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 8 (2), 191-197 (2007).
- Decalf, J., et al. Sensing of HIV-1 entry triggers a Type I Interferon response in human primary macrophages. J Virol. 91 (15), e00147-e00217 (2017).
- Wilson, A. A., et al. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest. 120 (1), 379-389 (2010).
- Markusic, D. M., van Til, N. P., Hiralall, J. K., Elferink, R. P., Seppen, J. Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain. BMC Biotechnol. 9, 85 (2009).
- Burke, B., Sumner, S., Maitland, N., Lewis, C. E. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol. 72 (3), 417-428 (2002).
- Bain, C. C., Jenkins, S. J. The biology of serous cavity macrophages. Cell Immunol. 330, 126-135 (2018).
- Milone, M. C., O’Doherty, U. Clinical use of lentiviral vectors. Leukemia. 32 (7), 1529-1541 (2018).
.